SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 34.66 |
| Enterprise Value ($M) | 17.35 |
| Book Value ($M) | 86.28 |
| Book Value / Share | 0.48 |
| Price / Book | 0.40 |
| NCAV ($M) | 17.20 |
| NCAV / Share | 0.09 |
| Price / NCAV | 2.02 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.44 |
| Return on Assets (ROA) | -0.37 |
| Return on Equity (ROE) | -0.42 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 6.75 |
| Current Ratio | 6.75 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 28.01 |
| Assets | 97.09 |
| Liabilities | 10.81 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 4.80 | 1.99 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,049,194 | 4,123,869 | 25.44 | |
| 1,167,050 | 3,748,366 | 31.13 | |
| 3,156,310 | 11,692,516 | 26.99 | |
| 3,166,771 | 10,708,054 | 29.57 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CRVO – CervoMed Inc. | CSBR – Champions Oncology, Inc. |
| CSCI – COSCIENS Biopharma Inc. | CUE – Cue Biopharma, Inc. |
| CVKD – Cadrenal Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io